Back to today’s briefing

Story perspectives

Breakthrough TAR-200 Implant Shows 82% Tumor Elimination Rate

8/19/2025

35 4

Summary

Story summary

The TAR-200 implant achieved an 82% tumor elimination rate in high-risk bladder cancer patients unresponsive to BCG therapy in a Phase 2 trial.
It delivers gemcitabine over three weeks, enhancing treatment effectiveness and minimizing invasive surgery.
Most side effects were mild, with a 3.5% treatment discontinuation rate.
TAR-200 has received FDA Breakthrough Therapy Designation, indicating its potential to change bladder cancer treatment.

1 of 1

Story summary

The TAR-200 implant achieved an 82% tumor elimination rate in high-risk bladder cancer patients unresponsive to BCG therapy in a Phase 2 trial.
It delivers gemcitabine over three weeks, enhancing treatment effectiveness and minimizing invasive surgery.
Most side effects were mild, with a 3.5% treatment discontinuation rate.
TAR-200 has received FDA Breakthrough Therapy Designation, indicating its potential to change bladder cancer treatment.